Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
BioSpace recently spoke with Yoav Kimchy, founder and chief technology officer of Check-Cap, a company developing the C-Scan® system to detect precancerous polyps.
Early data from a Phase III study for COVID-19 shows significant promise with its combo therapy reduced death and hospitalization in trial patients at high risk of progression by 78%.
The petition was posted on Monday by shareholder rights law firm Labaton Sucharow.
Rubix Life Sciences has launched a dedicated therapeutics division to focus on infectious and neurodegenerative diseases.
The development of COVID-19 vaccines, which took only months from the initial gene sequencing to the time shots were in arms, was the biggest story of 2020 alongside the pandemic itself.
Studies are also continuing on the value and efficacy of booster shots, particularly against the Delta variant. Read on for more information.
The current continues as investment dollars flow into the life sciences. Here’s an overview who is catching the drift this week.
The report also highlighted that an unvaccinated individual is five times more likely to get COVID-19 than someone who is fully vaccinated.
Atavistik Bio is linking a deep understanding of metabolite-protein interactions and their potential to lead to novel drugs that will restore protein function in metabolic diseases and cancers.
With a handful of drugs for cystic fibrosis already approved, Vertex Pharmaceuticals has turned its attention to expanding its pipeline through collaborations and acquisitions the past few years.
Shares of Tonix Pharmaceuticals were up nearly 11% in premarket trading after the company announced plans to initiate a Phase II study of TNX-102 SL as a potential treatment for Long COVID Syndrome following a positive meeting with the U.S. FDA.
President Biden is expected to be briefed on the lab leak theory conducted over the last 90 days. Very few expect solid results, although this might provide direction for more lines of inquiry.